Clinical Trials Logo

Amphetamine-related Disorders clinical trials

View clinical trials related to Amphetamine-related Disorders.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT02774954 Active, not recruiting - HIV Clinical Trials

Change the Cycle: An RCT to Prevent Injection Initiation

CTC
Start date: June 2016
Phase: Phase 3
Study type: Interventional

The study will test the efficacy of a hour long, one-on-one, active listening counseling session (called Change the Cycle or CTC) aimed at reducing behaviors among active people who inject drugs (PWID) that research has found to facilitate uptake of injection drug use among non-injectors. The study will involve ~1,100 PWID who will be randomized to CTC or an equal attention control intervention on improving nutrition. Participants will be recruited in Los Angeles and San Francisco, California and followed up at 6 and 12 months to determine changes in direct and indirect facilitation of injection initiation among non-injectors.

NCT ID: NCT02541513 Active, not recruiting - Heroin Dependence Clinical Trials

An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence

Start date: May 2013
Phase: Phase 3
Study type: Interventional

The proposed study will evaluate the tolerability, acceptability and potential efficacy of paliparidone for the treatment of co-occurring opioid and amphetamine-type stimulant (ATS) dependence. In the proposed clinical trial, all patients will first discontinue illicit opioid and ATS and be inducted onto buprenorphine maintenance treatment (BMT) in the inpatient ward at the department of psychiatry before beginning to receive paliparidone. Tolerability and acceptability will be evaluated by assessing the rates of patient retention during treatment, patient satisfaction with treatment and adverse effects during treatment. The potential efficacy of paliparidone will be evaluated with regard to the primary outcome measure: reductions in illicit ATS use, based on urine toxicology testing and self-report. Secondary outcome measures include treatment retention, reduction in HIV risk behaviors and improvements in functional status.

NCT ID: NCT01888835 Active, not recruiting - Clinical trials for Amphetamine-Related Disorders

Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)

Start date: August 2013
Phase: Phase 2
Study type: Interventional

The investigators recently conducted a double-blind, randomized controlled trial (n=60) of limited duration (12 weeks), and found that compared with placebo, oral mirtazapine, an FDA-approved antidepressant, significantly reduced meth use in those receiving mirtazapine, as determined by reduction in meth-positive urines. Sexual risk behaviors also declined significantly in the mirtazapine arm compared to placebo. Mirtazapine decreased meth use despite low adherence: by medical event monitoring system (MEMS) caps, only 48.5% of daily doses were taken. All participants received weekly substance use counseling and monthly, brief clinician-delivered adherence counseling. The investigators propose expanding upon these results by lengthening the treatment period to 24 weeks, with adherence reminders added to the counseling, and determining if efficacy is sustained up to 12 weeks after drug discontinuation. The sample size for this 9-month study is 120.

NCT ID: NCT00630097 Active, not recruiting - Clinical trials for Substance Dependence

A Dose Ranging Study of Modafinil for Methamphetamine Dependence

Start date: December 2009
Phase: Phase 2
Study type: Interventional

Patients treated for methamphetamine dependence have high rates of relapse, and no pharmacotherapy has yet been demonstrated to be efficacious. Modafinil (d, l-2-[(diphenylmethyl)sulfinyl]acetamide) is a novel wake- and vigilance-promoting agent that is chemically and pharmacologically dissimilar to CNS stimulants. It is well tolerated and has low abuse liability compared to CNS stimulants. Modafinil is FDA approved for a variety of sleep disorders, may relieve methamphetamine withdrawal symptoms, improves cognitive function, has been shown to reduce cocaine use in dependent users, and is safe when coadministered with intravenous methamphetamine. We will conduct a randomized dose ranging clinical trial of modafinil to establish its safety and efficacy as a pharmacotherapy for methamphetamine dependence.

NCT ID: NCT00267657 Active, not recruiting - Clinical trials for Amphetamine-Related Disorders

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

Start date: January 2004
Phase: Phase 1
Study type: Interventional

In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

NCT ID: NCT00265278 Active, not recruiting - Clinical trials for Amphetamine-Related Disorders

Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1

Start date: March 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral Modafinil.

NCT ID: NCT00123370 Active, not recruiting - Clinical trials for Amphetamine Dependence

Trial of Modafinil for Methamphetamine Dependence

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The study aims to evaluate the safety and efficacy of modafinil (200 mg/day) over 10 weeks plus a tailored cognitive behavioural therapy program in the treatment of methamphetamine dependence.

NCT ID: NCT00100074 Active, not recruiting - Clinical trials for Amphetamine-Related Disorders

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

Start date: September 2004
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

NCT ID: NCT00089440 Active, not recruiting - Clinical trials for Amphetamine-Related Disorders

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

Start date: June 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

NCT ID: NCT00040040 Active, not recruiting - Clinical trials for Amphetamine-Related Disorders

Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1

Start date: June 2002
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess potential interactions between intravenous (IV) methamphetamine and oral bupropion.